PROGRAM 

Note for physicians:
Attending the congress will be rewarded by up to 18 credit-points for continuing medical education by the "Bayerische Landesärztekammer"
 

 Click Here for Timetable
time

Download Program as PDF File

Sessions and Events at a Glance (click on session for further Information)
Sunday, 
March 13
Boveri Lecture Monday, 
March 14
Epigenetic Control 

Proteomics

Lung Cancer

Genetic Instability 

Gynaecologic Tumours and Breast Cancer

German Cancer Award
Tuesday, March 15 Biotechnology Boosts Oncology Wednesday, March 16 Chemoprevention and New Drugs
Stem Cells & Tumor Cells Animal Models
Tumor Stroma Interaction Homeostatic Growth Control
Urogenital Tumours Tumor Cell Metabolism
Soft Tissue Sarcoma Oesophageal / Gastric Cancer
Geriatric Oncology Pancreatic and Cholangiocellular Carcinoma
Political Platform Colorectal Cancer
AIO Awards Hepatobiliary Cancer

Neuroendocrine and Endocrine Tumours


Poster Exhibition
Posters will be up throughout the congress, however the lunch breaks will be especially dedicated to the posters corrsponding to the day's sessions. During the lunch break the respective presenting authors are expected to attend their posters.
Monday, 
March 14
 
 
 

 

Epigenetic Control  Tuesday, March 15 Biotech Boosts Oncology
Proteomics Stem Cells & Tumor Cells
Lung Cancer Tumor Stroma Interaction
Genetic Instability Urogenital Tumours
Gynaecologic Tumours and Breast Cancer Soft Tissue Sarcoma

Geriatric Oncology
Wednesday,
March 16
 
 

 

Chemoprevention and New Drugs

Animal Models

Homeostatic Growth Control

Tumor Cell Metabolism

Gastro Intestinal Tumors

Neuroendocrine and Endocrine Tumours

Sessions

Sunday, March 13 
from 13:00  Registration 
19:00 
-
21:00 
„Boveri Award” Lecture

David M. Livingston, Boston
Functional Analysis of the BRCA1 Gene

Laudatio: Peter Vogt, La Jolla

Event accompanied by a concert of the "Voces Quartet"



 
 

Monday, March 14 

Joint AEK/AIO Session 
"Epigenetic Control"; Part 1: "DNA- and Histone-Modifications"

Chair: U. Rapp, Würzburg, B. Dörken, Berlin

08:30  Frank Lyko, Heidelberg
O-1 Characterization of DNA methyltransferase inhibitors: new drugs for an epigenetic cancer therapy
09:00  Ingrid Grummt, Heidelberg
O-2 The chromatin remodeling complex NoRC mediates heterochromatin formation, silences rRNA transcription and controls replication timing
09:30  Manel Esteller, Madrid
O-3 Cancer Epigenetics: Breaking the DNA Methylation and Histone Codes
10:00 Pier Giuseppe Pelicci, Milan
O-4 Inhibitors of Histone Deacetylases Induce Apoptosis Selectively in Leukemia Cells through Activation of the Death Receptor Pathway 
10:30 Coffee and Industrial Exhibition

Joint AEK/AIO Session
"Epigenetic Control"; Part 2: "The Role of RNA"

Chair: F. Lyko, Heidelberg, E. Jäger, Frankfurt

11:00  I-hung Shih, Cambridge
O-5 Regulatory Roles of Mammalian MicroRNAs
11:30  Carlo M. Croce, Columbus
O-6 Micro RNAs in Human Cancer
12:00  Nick La Thangue, Glasgow
O-7 Regulation of the p53 response
12:30 Peter Jones, Los Angeles
O-8 Epigenetic Therapy
13:00  Lunch at the Industrial Exhibition and Posters
  AEK Session 
"Proteomics"

Chair:  M. Schartl, Würzburg, P. Vogt, La Jolla 


AIO Session
"Lung Cancer"

Chair: N. Niederle, Leverkusen; G. Sybrecht, Homburg 

14:00 Giulio Superti-Furga, Vienna
O-9 Proteomics, systems biology and molecular medicine
14:00 W. Eberhardt, Essen
O-17 Standards in systemic chemotherapy in lung cancer
14:25 Ben Cravatt, La Jolla 
O-10 Profiling enzyme activities in human cancer
14:15 R. Pirker, Wien
O-18 Mechanisms of chemoresistance
14:50 Julio Celis, Aarhus
O-11 Translational Research in Breast Cancer: An Integrated Vision
14:30 F. Griesinger, Göttingen
O-19 EGF-receptor therapies
15:15 John Yates, La Jolla
O-12 Towards Comprehensive Analysis of Cells and Tissues
14:45 R. Huber, Munich
O-20 Anti-angiogenetic strategies in thoracic oncology


15:00 A. Schmittel, Berlin
O-21 Immune therapeutic approaches in lung cancer


15:15 N. Niederle, Leverkusen
O-22 Perspectives in clinical research
15:40 Coffee and Industrial Exhibition 15:30 Coffee and Industrial Exhibition
  AEK Session 
"Genetic Instability"

Chair: D. Livingston, Boston; E. Nigg, Munich


AIO Session
"Gynaecologic Tumours and Breast Cancer" 

Chair: K. Possinger, Berlin; F. Overkamp, Recklinghausen

16:00 Ian Tomlinson, London
O-13 Genetic instability and cancer: when, where and how much?
16:00 V. Heinemann, Munich
O-23 Standards in systemic chemotherapy in breast cancer
16:30 Erich Nigg, Martinsried
O-14 Centrosome aberrations and chromosomal instability in cancer
16:20 P. Schmid, Berlin
O-24 Hormone resistence and modulation 
17:00 Petra Boukamp, Heidelberg
O-15 Telomeres and their role in chromosomal instability
16:40 P. Brossart, Tübingen
O-25 Signal transduction via EGF- und VEGF-receptors
17:30 Christoph Klein, Munich
O-16 Genetic heterogeneity and systemic cancer progression
17:00 F. Overkamp, Recklinghausen
O-26 Neoadjuvant therapy 


17:20 K. Possinger, Berlin
O-27 Perspectives in clinical research
18:00  19:00 German Cancer Award
Reception, accompanied by "Richard Roblee's Very Little Big Band"


Tuesday, March 15
  Joint AEK/AIO Session 
"Biotechnology Boosts Oncology"; Part 1

Chair: S. Schröder-Köhne, Würzburg

08:30 Rüdiger Ridder, MTM Laboratories AG, Heidelberg
O-28 Biomarkers as an Emerging Approach to Improve Cancer Early Detection
09:00 Jens Hennecke, Micromet AG, Munich
O-29 Induction of a Polyclonal T Cell Response for Human Therapy
09:30 Andreas Wiesner, Ciphergen Biosystems
O-30 SELDI-TOF-MS based protein marker discovery and clinical assay development
10:00 Eckart Kämpgen, Argos Therapeutics GmbH, Erlangen 
O-31 Title to follow
10:30  Coffee and Industrial Exhibition
  Joint AEK/AIO Session 
"Biotechnology Boosts Oncology"; Part 2

Chair: Ulrich Keilholz, Berlin; G. Superti-Furga, Vienna

11:00 Axel Wiest, Fresenius Biotech GmbH, Munich
O-32 Title to follow
11:30 Sybille Mazurek, Schebo Biotech AG, Giessen
O-33 Pyruvate kinase type M2: a key regulator of the tumor metabolome with high diagnostic and therapeutic potential 
12:00 Erik Jans, BioSource Europe S.A., Nivelles
O-34 Analysis of complex Signaling Pathways Using a Phosphorylation Site-Specific Array: Cutting-Edge Tool for Discovery
12:30 Andreas Braun, Sequenom, San Diego 
O-35 Identification of Breast Cancer Susceptibility Genes by Genome-Wide Association Mapping
13:00  Lunch at the Industrial Exhibition and Posters
  AEK Session
"Stem Cells & Tumor Cells - Close Relatives?" 

Chair: T. Möröy, Essen; A. Müller, Würzburg


AIO Session
"Urogenital Tumours"

Chair: C. Bokemeyer, AIO, Hamburg; J. Claßen, ARO, Tübingen

14:00  Andreas Trumpp, Epalinges
O-36 Control of hematopoietic stem cell fate by c-Myc regulated adhesion to the bone marrow niche
14:00 L. Looijenga, Rotterdam
O-43 Biology of testicular cancer
14.30 Peter Friedl, Würzburg
O-37 Molecular plasticity of disseminating cancer cells
14:20 J. Claßen (ARO), Tübingen
O-44 Radiotherapy for testicular seminoma: Clinical trials and experimental basis for research in late effects of treatment
15:00 Maarten van Lohuizen, Amsterdam
O-38 Polycomb repressors controlling stem cell fate: Implications for cancer and development
14:40 P. Albers (AUO), Kassel
O-45 Non-seminoma: Early stages Clinical trials and molecular prognostic factors


15:00 F. Honecker, Hamburg
O-46 Platinum resistance in germ cell tumours: Molecular biology and novel therapeutic approaches


15:20 C. Bokemeyer, Hamburg
O-47 Summary: Perspectives in clinical cancer research
15:30  Coffee and Industrial Exhibition
  AEK Session
"Tumor Stroma Interaction"

Chair: P. ten Dijke, Leiden; P. Friedl, Würzburg


AIO Session
"Soft Tissue Sarcoma" 

Chair: P. Reichardt, Berlin; J. Schütte, Düsseldorf

16:00 Peter ten Dijke, Leiden
O-39 TGF-beta receptor signal transduction in angiogenesis
16:00 J.T. Hartmann, Tübingen
O-48 Current treatment strategies in adult soft tissue sarcoma 
16:30 David Cheresh, La Jolla
O-40 Unexpected Role of VEGF in Tumor Cell Invasion and Metastasis
16:12 R. Issels, Munich
O-49 The role of hyperthermia in the treatment of locally advanced soft tissue sarcoma
17:00 Jürgen Knoblich, Wien
O-41 Tumor suppressors and neuronal stem cells - lessons from Drosophila
16:24 M. Schlemmer, Munich
O-50 Secondary resistance to imatinib and novel treatment options in GIST
17:30 Eugen Kerkhoff, Würzburg
O-42 Cytoskeletal organization and cell polarity: Spir nucleates actin polymerization by a novel Arp2/3 independent mechanism
16:36

16:44

P. Reichardt, Berlin
O-51 Perspectives in clinical research 
General Discussion


  AIO Session
"Geriatric Oncology" 

Chair: U. Wedding, Jena 



17:00 I. Irminger, Genf
O-52 Molecular crossroads of cancer and aging


17:25 U. Wedding, Jena
O-53 Perspectives in clinical research



AIO Session
"Political Platform" 

Chair: G. Ehninger, Dresden; H.-J. Schmoll, Halle



17:35 H. Link, Kaiserslautern 
O-54 Quality assurance and standardisation: Internet based protocol platform


17:55 U. Keilholz, Berlin
O-55 Future of clinical research / cost aspect (off label), industry based support


18:15  G. Adler, Ulm
O-56 How will clinical research be supported in future?
18:35 - 19:00 AIO-Awards
19:45 Banquet at the "Würzburger Residenz" (ticket required)


Wednesday, March 16

Joint AEK/AIO Session 
"Chemoprevention and New Drugs"

Chair: Guido Adler, Ulm; Axel Ullrich, Singapore


GITSG-DKG Session
"Oesophageal / Gastric Cancer" 

Chair: A. Hoelscher, Köln; R. Fietkau, Rostock; E. Jäger, Frankfurt

08:30  Axel Ullrich, Singapore 
O-57 Smart Cancer Drugs: From Target-Specific to Multitargeted Therapies
09:30 M. Stahl, Essen
O-73 Oesophageal cancer: Standards and clinical trials
09:00 Martin Göttlicher, Neuherberg
O-58 Specific Functions of Histone Deacetylase 2 in Colonic Cancer and Embryonic Development
09:40 R. Fietkau, Rostock
O-74 Modern chemoradiation – a curative approach in oesophageal cancer?
09:30 Bernd Groner, Frankfurt 
O-59 The Deployment of Peptide Aptamers in the Interference with Crucial Signaling Events in Cancer Cells
09:50 H.-J. Meyer, Solingen
O-75 Oesophageal and gastric cancer: Perioperative adjuvant strategies and quality-assessed surgery
10:00 Helmut Bartsch, Heidelberg
O-60 Molecular Chemoprevention Research on Early Reversal of Carcinogenesis
10:00 H. Wilke, Essen
O-76 Gastric cancer: Is perioperative therapy a standard yet?


10:15 F.Lordick, München
O-77 Novel drugs in gastric cancer: Extension of chemotherapeutic options
10:30  Coffee and Industrial Exhibition

Joint AEK/AIO Session 
"Animal Models"

Chair: M. Eilers, Marburg; N.N.


GITSG-DKG Session
"Pancreatic (and Cholangiocellular) Carcinoma"

Chair: P. Neuhaus, Berlin; M. Flentje, Würzburg; G. Adler, Ulm

11:00  Dario Alessi, Dundee
O-61 Functional analysis of PDK1 and LKB1 signalling pathways
11:00 V. Heinemann, Munich
O-78 Systemic chemotherapy: Is Gemcitabine still standard of care?
11:30 Jos Jonkers, Amsterdam
O-62 Conditional mouse models of breast cancer
11:10 M. Geissler, Freiburg
O-79 AIO - trials in palliative systemic therapy
12:00 Thomas Wirth, Ulm (short talk)
O-63 Conditional lymphomagenesis in mice
11:20 H. Friess, Heidelberg
O-80 Multimodal therapy of pancreatic carcinoma
12:15 Ulf Rapp, Würzburg (short talk)
O-64 Raf/Myc cooperation in lung tumor induction in mice
11:30 N.N.
O-81 Adjuvant radiochemotherapy or chemotherapy: What is the evidence?
12:30 Tarik Möröy, Essen
O-65 Transcription factor Gfi1 regulates self-renewal and long-term engraftment abilities of hematopoietic stem cells by regulating their proliferation and survival
11:40 G. Grabenbauer, Erlangen
O-82 Multimodal therapy: Novel trials with neoadjuvant intention
O-83 Multimodal therapy: Novel trials with palliative intention



GITSG-DKG Session
"Colorectal Cancer" 
Part 1 - Rectal Cancer

Chair: P.M. Schlag, Berlin; H.-J. Schmoll, Halle



12:00 H. Becker, Göttingen
O-84 The influence of neoadjuvant radiochemotherapy on perioperative risk


12:15 W. Hohenberger, Erlangen
O-85 After neoadjuvant radiochemotherapy: Is a higher rate in sphincter preservation achievable – and should we go for it in any situation? 


12:30 C. Rödel, Erlangen
O-86 The CAO/AIO/ARO-94 trial: What lessons have we learned?


12:45 M. Flentje, Würzburg
O-87 Moving on from this: Modification and optimization of the new standard - what are the potential benefits and risks in radiotherapy?


13:00 D. Arnold, Halle
O-88 Moving on from this: Modification and optimization of the new standard - what are the potential benefits and risks in chemotherapy?
13:00 Lunch at the Industrial Exhibition and Posters 13:15

AEK Session 
"Homeostatic Growth Control"

Chair: K. Bister, Innsbruck, H. Grunicke, Innsbruck 


GITSG-DKG Session
"Colorectal Cancer" 
Part 2: Colon cancer in metastatic and limited stages: Optimal multimodal strategies

Chair: P.M. Schlag, Berlin; H.-J. Schmoll, Halle; ARO (N.N.)

14:00 Chris Marshall, London
O-66 Interactions between GTPase signalling pathways in tumour biology
14:00 J. Jähne, Hannover
O-89 - in peritoneal carcinomatosis
14:30 Martin Eilers, Marburg
O-67 Strategies to interfere with Myc function in human tumors
14:15 W. Bechstein, Frankfurt
O-90 - in isolated liver metastasis: Results and future plans in resectable and non-resectable stages
15:00 Piero Crespo, Santander
O-68 Distinct utilization of effectors and biological outcomes resulting  from site-specific Ras activation: Ras functions in lipid rafts and  Golgi complex are dispensable for proliferation and transformation
14:30 G. Folprecht, Dresden
O-91 - in stage II colon cancer: Is surgery alone sufficient?



GITSG-DKG Session
"Colorectal Cancer" 
Part 3: Metastatic disease - Systemic options

Chair: W. Bechstein, Frankfurt; W. Schmiegel, Bochum



14:45 U. Graeven, Mönchengladbach
O-92 Standards in chemotherapy 2005


15:00 W. Schmiegel, Bochum
O-93 What can we expect from the other novel drugs targeting EGF-R, VEGF and others?


15:15 J. Stöhlmacher, Hamburg
O-94 Molecular predictive and prognostic factors: Still a fiction or almost a standard?
15:30  Coffee and Industrial Exhibition

AEK Session 
"Tumor Cell Metabolism"

Chair: C. Marshall, London; J. Pouyssegur, Nice


GITSG-DKG Session
"Colorectal Cancer" 
Continued Part 3: Metastatic disease - Systemic options

Chair: W. Bechstein, Frankfurt; W. Schmiegel, Bochum

16:00 Peter Vogt, La Jolla
O-69 PI3K-Dependent Oncogenesis Requires Changes in Transcription and Translation
16:00 D. Arnold, Halle; T. Seufferlein, Ulm
O-95 Perspectives in clinical trials: The AIO portfolio 2005
6:30 Wilhelm Krek, Zürich
O-70 Cell-cycle signalling networks and cancer

GITSG-DKG Session
"Hepatobiliary Cancer" 

Chair: W. Fleig, Halle; P. Neuhaus, Berlin

17:00 George Thomas, Cincinnati
O-71 The mTOR-Inhibitor RAD001 Sensitizes Tumor Cells to DNA-damaged Induced Apoptosis Through Inhibition of p21 Translation
16:20 L. Mohr, Freiburg
O-96 Hepatocellular Carcinoma:
- Innovative and experimental therapeutic approaches and studies
17:30 Jacques Pouyssegur, Nice
O-72 Hypoxia signaling and Tumor progression
16:40 J. Schlitt, Regensburg
O-97 Hepatocellular Carcinoma: 
- Drug and surgical therapy and clinical trials
 

GITSG-DKG Session
"Neuroendocrine and Endocrine Tumours" 

Chair: U. Plöckinger, Berlin; G. Brabant, Hannover



17:00 U. Plöckinger, Berlin
O-98 Advances in therapy of neuroendocrine malignant diseases: The novel NET register 


17:20 U. Plöckinger, Berlin
O-99 Clinical trials in neuroendocrine tumours


17:40 B. Allolio, Würzburg
O-100 Adrenal cancer – novel developments and clinical trials


17:55 W. Hohenberger
Summary 

Poster Exhibition
Posters will be up throughout the congress, however the lunch breaks will be especially dedicated to the posters corrsponding to the day's sessions. During the lunch break the respective presenting authors are expected to attend their posters.

The three best posters will be awarded with a poster price
sponsored by faustus
Faustus Forschungs Compagnie Translational Cancer Research GmbH Monday- Tuesday - Wednesday
 

Monday

Epigenetic Control
PE-1 The presumptive cancer-testis antigen CTCFL is regulated by DNA methylation 
Michèle J. Hoffmann, Mirko Müller, Andrea R. Florl, Wolfgang A. Schulz (Düsseldorf, Germany)
PE-2 Neuroblastoma cell differentiation towards mature ganglionic cells by the histone deacetylase inhibitor valproic acid 
Hedwig Deubzer, Johannes Schulte, Martin Michaelis, Jindrich Cinatl, Lothar Schweigerer, Jörg Hoheisel, Olaf Witt (Göttingen, Germany)
PE-3 Promoter methylation profile of tumor-related genes in thyroid cancer 
Reinhard Dammann, Cuong Hoang Vu, Undraga Schagdarsurengin (Halle, Germany)
PE-4 Identification and characterization of differentially methylated genes during glioma progression using microarray analysis and cRT-PCR 
J. Felsberg, D. Ehrentraut, P. S. Yan, T. Pietsch, J. Schramm, O. D. Wiestler, G. Reifenberger, A. Waha (Bonn, Germany)
PE-5 Modulation of epigenetic processes in HRAS-transformed fibroblasts 
Christine Sers, Karen Weißhaupt, Thomas Mikeska, Diana Jammas, Xiaohua Chen, Ralf-Jürgen Kuban, Ute Ungethüm, Ulf Krapfenbauer, Hans-Peter Herzel, Reinhold Schäfer, Jörn Walter, Per Lund (Berlin, Germany)
PE-6 Identification of epigenetically altered genes in medulloblastomas by CpG microarray analysis 
A. Waha, A. Koch, W. Hartmann, J. Felsberg, U. Milde, D. Ehrentraut, N. Sörensen, F. Berthold, O. D. Wiestler, T. Pietsch, A. Waha (Bonn, Germany)
PE-7 5-aza-2’-deoxycytidine causes a complex response in patients with myelodysplastic syndrome 
Mund, C., Hackanson, B., Luebbert, M., Lyko, F. (Heidelberg, Germany)
PE-8 Microsatellite- and hypermethylation-analysis at the RASSF1A-locus of renal cell carcinoma patients 
K. Blümke, F. Bartel, R. Dammann, U. Schagdarsurengin, U. Bilkenroth, A. Melchior, T. Schneider, H. Taubert, H. Heynemann, P. Fornara (Halle, Germany)
PE-9 Expression of G1-S Cell Cycle Proteins In Laryngeal Carcinoma And Their Relation To Clinicopathological Variables And Patient Survival 
Marcin Fraczek, Tomasz Krecicki, David Ramsey, Zdzislaw Wozniak (Wroclaw, Poland)
PE-10 Transcriptional regulation of Cyclin A2 by RASSF1A through the enhanced binding of p120E4F to the Cyclin A2 promoter 
J. Ahmed-Choudhury, A. Agathanggelou, S. L. Fenton, C. Ricketts, G. J. Clark, E. R. Maher, F. Latif (Birmingham, UK)
PE-11 Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia 
Oliver Galm, Stefan Wilop, Christian Lüders, Edgar Jost, Gerald Gehbauer, James G. Herman, Rainhardt Osieka (Aachen, Germany)
PE-12 withdrawn
PE-13 Quantitative methylation profiling of ductal-invasive and lobular-invasive mammary carcinoma 
Ulrich Lehmann, P. Ahrens, L. U. Wingen, B. Schlegelberger, F. Länger, H. Kreipe (Hannover, Germany)
PE-14 GR inhibits hFasL expression in a DNA binding-dependent manner 
Natalia Novac, Anja Dostert, Thorsten Heinzel  (Frankfurt a.M., Germany)
PE-15 Detailed p16INK4a methylation patterns in HPV-associated tumors 
Kristina Nehls, Nicolas Wentzensen, Svetlana Vinokurova, Magnus von Knebel Doeberitz (Heidelberg, Germany)
PE-16 Altering the dynamic properties of HMGA protein and consequences for chromatin structure and function 
Jan Brocher, Robert Hock, Monika Schütz (Würzburg, Germany)

Proteomics
PP-1 The LIM domain protein CRP2 interacts with EB1, a binding partner of the human tumor suppressor APC 
Theresia Matt, Elizabeth Dowler, Haymo Pircher, Markus Hartl, Paul Schanda, Georg Kontaxis, Klaus Bister, Robert Konrat (Innsbruck, Austria)
PP-2 A Novel Reverse Phase Immunoassay for PSA Analysis in Serum 
Martin Olbrich, N. Bewarder, H.J. Staab (Tübingen, Germany)
PP-3 Identification of new proteins in Xmrk-signaling by a differential proteomics approach 
Christiane Stuhlfelder, Manfred Schartl, Albert Sickmann (Würzburg, Germany)

Lung Cancer
PL-1 Detection of deletions, point mutations and single nucleotide polymorphisms in the human EGF receptor tyrosine kinase domain in tumor samples from non-small cell lung cancer patients 
H. Lahm, T. Muley, M. Zemaitis, P. Schnabel, H. Dienemann, P. Drings, J. R. Fischer, M. Meister (Heidelberg, Germany)
PL-2 Withdrawn
PL-3 Promotor-methylation profiling in lung cancer using MALDI TOF Mass Spectrometry 
Mathias Ehrich, Triantafillos Liloglou, John Field, Matthew R. Nelson, Dirk van den Boom (San Diego, USA
PL-4 BAG-1 haplo-insufficiency impairs lung tumorigenesis 
Rudolf Götz, Fatih Ceteci, Boris Kramer  and Ulf R. Rapp (Würzburg, Germany)
PL-5 Analysis of the role of E-cadherin in lung tumorigenesis 
Fatih Ceteci, Rudolf Götz, Boris Kramer, Esther Asan and Ulf R. Rapp (Würzburg, Germany)
PL-6 Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice
Ivaylo Gentschev,Joachim Fensterle, Andreas Schmidt, Tamara Potapenko, Jakob Troppmair, Werner Goebel, Ulf R. Rapp (Würzburg, Germany)

Genetic Instability
PG-1 Global Gene Expression Profiling of Prostate Cancer for Target Discovery 
Bernard Händler, Hellmuth-Alexander Meyer, Anette Sommer, Lutz Konrad, Rainer Hofmann, Helmut Klocker, Jörn Krätzschmar, Henrik Seidel /Berlin, Germany)
PG-2 A new candidate region for a tumor suppressor in 13q31.1-32.1 for laryngeal squamous cell carcinoma 
N. Blin, Agnieszka Stembalska, Maria M. Sasiadek (Tübingen, Germany)
PG-3 Increasing detection efficiency of microsatellite instabilities in colon carcinoma by applying a label-free method 
Ruediger Salowsky, N. Barta, H.P. Dienes, S. Lammers, S. E. Baldus, and M. Odenthal (Waldbronn, Germany)
PG-4 Genotoxicity of nicotine in human target cells 
Kleinsasser N, Richter E, Harreus U, Semmler M, Sassen A (Regensburg, Germany)
PG-5 Chromosomal aberrations and differential gene expression in non-tumorigenic and tumorigenic hybrid cells 
K. Kleine-Lowinski, A. Kehrmann, A. Repenning, Esche H., Seeber S. (Essen, Germany)
PG-6 Chromosome microdissection revealed genomic amplification in a drug resistance cell line: Application in Clinic 
Frouzandeh Mahjoubi, Ron Hill, Greg Peters (Tehran, Iran)
PG-7 Interstitial loss and gain of sequences on chromosome 22 in meningiomas with normal karyotype 
Alexandra Prowald, Steffi Urbschat, Silke Wemmert, Eckart Meese, Klaus D. Zang, Wolf-Ingo Steudel (Homburg/Saar)
PG-8 Investigation of the L5178Y Mouse Lymphoma Cell Line Concerning its Mismatch Repair 
Katja Kampfinger, Helga Stopper (Würzburg, Germany)
PG-9 Mismatch Repair Defects and Infertility in Mice Carrying the Mlh1G67R Missense Mutation 
Cora Reiß,  Stefan J Scherer, Paula Cohen, Sunhee Baek, Raju Kucherlapati, Winfried Edelmann and Burkhard Kneitz (Würzburg, Germany)
PG-10 AT1 Receptor Blockade with Candesartan Decreased Genotoxicity of Angiotensin II in LLC-PK1 Cells and in a Small Group of Hemodialysed Patients
Helga Stopper, U. Lakner, N. Schupp, P.Rutkowski and A. Heidland (Würzburg, Germany)
PG-11 Wilms’ tumor molecular genetics: Correlation of clinical parameters with LOH and candidate gene expression 
Stefanie Wittmann, Birgit Zirn, Barbara Klamt, Manfred Gessler, Norbert Graf (Würzburg, Germany)
PG-12 MALT1 Dysregulation in Lymphomagenesis 
Daiva-Elzbieta Optazaite, Mindaugas Andrulis, Thamathorn Assanasen, Hans Konrad Müller-Hermelink, Axel Greiner (Würzburg, Germany)

Gynaecologic Tumours and Breast Cancer
PB-1 Determination of TOP2A gene alteration related to HER-2 gene amplification in breast cancer 
Natasa Todorovic-Rakovic, Zora Neškovic-Konstantinovic, Dragica Nikolic-Vukosavljevic (Belgrade, Serbia and Montenegro)
PB-2 Cathepsin D-related Disease-free Interval in pT1 Primary Breast Carcinomas 
Milan Markicevic, D. Nikolic-Vukosavljevic, G. Grujic-Adanjab, A. Petrovic, I. Kezic, Z. Neskovic-Konstantinovic (Belgrade, Serbia and Montenegro)
PB-3 Functional characterization of the breast cancer antigen NY-BR-1 
Inka Seil, Silke Deckert, Elke Jäger, Dirk Jäger, Roland Stauber (Frankfurt a.M., Germany) 
PB-4 O6-AGT-mediated cytotoxicity of treosulfan in ovarian cancer? No reduction of activity following O6-AGT depletion 
Büch TR, Zeller WJ (Heidelberg, Germany)
PB-5 Combination of Lasermicrodissection and Microarray Analysis to determine progression-specific molecular Markers in Breast Cancer 
Christina Schütz, Hans Neubauer, Michael Bonin, Susan Clare, Karl Sotlar, Olaf Rieß, Diethelm Wallwiener, and Raffael Kurek (Tübingen, Germany)
PB-6 The role of estrogen receptor (ER) beta for the human mammary carcinoma MCF-7 
Diana Behrens, Iduna Fichtner (Berlin, Germany)
PB-7 Effect of cell membrane organisation of MT3 breast cancer cells on adhesion to immobilised E-selectin 
Diana Behrens, R. Zeisig, T. Koklic, I. Fichtner, M. Sentjurc (Berlin, Germany)
PB-8 Characterization of a humoral immune response against p16INK4a in cervical cancers 
Miriam Reuschenbach, Nicolas Wentzensen, Peter Sehr, Jens Einenkel, Michael Pawlita, Magnus von Knebel Doeberitz (Heidelberg, Germany)
PB-9 Keratin 18 transfected human breast cancer cells exert a „benign“ influence on adjacent wild type cells – a bystander effect with encouraging implications for a successful gene therapy 
Helmut Bühler, Blanka Duvnjak, Gerhard Schaller (Bochum, Germany)
PB-10 Mammalian Target of Rapamycin Signalling is Required for Functional Differentiation of Mammary Gland Epithelial Cells
Marcin Jankiewicz , Sylvane Desrivières and Bernd Groner (Frankfurt a.M., Germany) 


Tuesday

Biotechnology Boosts Oncology
PBB-1 DHPLC and direct sequencing mutational analysis of KIT/PDGFRA genes in GISTs: A study of 75 cases 
Anna Piskorz, B. Wasag, A. Wozniak, M. Chosia, J. Stachura, W. Ruka, J. Limon (Gdansk, Poland)
PBB-2 High Throughput Experimental Verification of Predicted Tissue and Tumor Specific Splice Isoforms 
Carsten Buhlmann, Dorothea Zink, Ruediger Salowsky, Stefan Haas and Bernhard Korn (Waldbronn, Germany) 
PBB-3 Global gene expression analysis in Head and Neck Squamous Cell Carcinomas using microarray analysis 
Hartmut Walendzik, N. Habtemichael, A. F. Kovács, R. Stauber (Frankfurt a.M., Germany)
PBB-4 Multiphoton tomography of human skin in vivo 
A. Ehlers, I. Riemann, T. Anhut, E. Dimitrow, M. Kaatz, J. Fluhr, P. Elsner, J. Kobow, K. König (St. Ingbert, Germany)
PBB-5 Engineering of Oncolytic Adenoviruses for Targeted and Efficient Virotherapy of Cancer 
D. M. Nettelbeck, S. Schierer, D. Kosmides, A. A. Rivera, A. Hesse, A. Mainka, A. L. Volk, D. T. Curiel, G. Schuler (Erlangen, Germany)
PBB-6 An efficient transgenesis system for the functional testing of candidate disease genes 
Armin Pscherer, Julia Schliwka, Kathrin Wildenberger, Antoaneta Mincheva, Carsten Schwaenen, Hartmut Döhner, Stephan Stilgenbauer & Peter Lichter (Heidelberg, Germany)
PBB-7 Translocation Biosensors to Study Signal Specific Nucleo-Cytoplasmic Transport and Protein-Protein Interactions of Cancer Relevant Targets 
Shirley K. Knauer, Gert Carra and Roland H. Stauber (Frankfurt, Germany)
PBB-8 High-resolution in Elispot measurements with regard to multiple labels 
Wolf Malkusch (Hallbergmoos, Germany)
PBB-9 Development of a new screening approach for predictive gene sets in cancer 
Andreas Rühlmann, Rainer Wittig, Ruediger Salowsky, Annemarie Poustka (Waldbronn, Germany)

Stem Cells & Tumor Cells - CloseRelatives?
PS-1 Lipid raft protein composition distinguishes stem cells from tumour cells 
Ralf Huss, Anja Osterhues, Sybille Liebmann, Lutz Graeve, Evelyn Zeindl-Eberhart (Munich, Germany)
PS-2 In vitro cytokine-induced expression of homing related adhesion molecules on CD34+ cord blood stem cells, hepatic differentiation and engraftment in NOD/SCID mice 
Annika Wulf, Klaus Eckert, Iduna Fichtner (Berlin, Germany)
PS-3 The stem cell marker, Musashi-1 (MSI-1) is expressed in intestinal-type, but not in diffuse-type gastric cancers 
Stacy Carl-McGrath, Jie Chen, Matthias Ebert, Albert Roessner, Christoph Röcken (Magdeburg, Germany)
PS-4 VH Gene and Clonality Analysis of B-CLL and DLBCL in Richter Syndrome 
Zhengrong Mao, Falko Fend, Christof Burek, German Ott, Hans Konrad Mueller-Hermelink, Andreas Rosenwald (Würzburg, Germany)
PS-5 Onset of thymic recovery and plateau of thymic output are differentially regulated after stem cell transplantation in children
Eyrich Matthias, Wollny Gernot, Tzaribaschev Nikolaj, Dietz Klaus, Schilbach Karin, Winkler Beate, Niethammer Dietrich, and Schlegel Paul G.

Urogenital Tumours
PU-1 Proteomics-based NMP22-BladderChek in early bladder cancer detection 
Oehr P (Bonn, Germany)
PU-2 The green tea flavonoid (polyphenolic plant constituent) (-)–epigallocatechin-3-gallate (EGCG) induces rapid cell death in human prostate cancer cell lines (LNCaP, PC-346C)
Nishino T, Roy S, Whyte L, Denis C, Jeffrey R, Buehlmeyer K, Schulz T, Michna H and Tenniswood M (Munich, Germany)
PU-3 Expression profiling of hTERT antisense treated bladder cancer cells 
A. Meye, Kai Krämer, Uta Schmidt, Susanne Füssel, Manfred Wirth (Dresden, Germany)
PU-4 Polymerisation Properties of the Cancer/Testis Antigen SCP1 
Rupert Öllinger, Manfred Alsheimer, Ricardo Benavente (Würzburg, Germany)

Tumor Stroma Interaction
PT-1 Differentiation induction of leukaemic cells in vitro: Validation of stromal environment-induced differentiation of human AML cells 
Kallal Pramanik, Axel Greiner, Albrecht M. Müller (Würzburg, Germany)
PT-2 Guanylate Binding Protein-1 is a Molecular Marker and Regulator of Inflammatory Tumor-Stroma Cell Interaction in Colon Carcinoma 
M. Stürzl, E. Naschberger, C. Lubeseder-Martellato, E. Kremmer, T. Papadopoulos, W. Hohenberger (Erlangen, Germany)
PT-3 Molecular mechanisms of intrinsic and acquired chemoresistance of pancreatic carcinoma cells 
V. Werbing, S. Müerköster, J. Lust, K. Wegehenkel, A. Arlt, M. Witt, M.-L. Kruse, T. Sebens, U. R. Fölsch, H. Schäfer (Kiel, Germany)
PT-4 Expression of the actin-binding protein L-plastin enhances migration and invasion of human melanoma cells 
Martin Klemke, Maria T. Rafael, Tatjana Weschenfelder, Wolfgang Hartschuh, Yvonne Samstag (Heidelberg, Germany)
PT-5 Interaction of the transcription factor osf2 with the progression markers osteopontin, bone sialoprotein and osteonectin in vitro 
Ergyl Eyol, Hassan Adwan, Martin R. Berger (Heidelberg, Germany)
PT-6 Osteonectin influences growth and invasion of pancreatic cancer cells 
Michael W. Müller, Jörg Kleeff, Moritz Wente, Nathalia Giese, Markus W. Büchler, Helmut Friess (Heidelberg, Germany)
PT-7 The matrix metalloproteinase-9 hemopexin domain (MMP-9-PEX): A potent inhibitor of adhesion and migration in colorectal carcinoma? 
Sandra Wagner, Martin Roderfeld, Katja Strick, Siegfried Matern, Elke Roeb (Aachen, Germany)
PT-8 Galectin-1: a novel target of p16ink4a that sensitizes carcinoma cells to anoikis via the a5b1 fibronectin receptor 
H. Sanchez Ruderisch, K. M. Detjen, M. Buchholz, M. Welzel, S. André, A. Wimmel, B. Wiedenmann, T. M. Gress, H.-J. Gabius & S. Rosewicz (Berlin, Germany)
PT-9 Transcript profiling of osteocytes from native human bone microdissections: High-quality RNA preparation 
Sabine Eisenberger , K. Ackermann,  G. Hoppe, G. Voggenreiter,  C. Kasperk, W. Pyerin (Heidelberg, Germany)
PT-10 The EGFR family protein Xmrk influences the turnover of FAK and enables melanocyte migration 
Svenja Meierjohann, Anita Kraiß, Elisabeth Wende, Manfred Schartl (Würzburg, Germany)
PT-11 Intratumoral Lymphocytic Infiltrates Correlate with the Expression of MHC Class I in Advanced Melanoma 
Reza Rafiyan, Salah E. Al Batran, Michael Altmannsberger, Antje Neumann, Julia Karbach, Kerstin Franzmann, Akin Atmaca, Eckhart Weidmann, Armin Bender, Dirk Jäger, Alexander Knuth, Elke Jäger (Frankfurt a.M., Germany)
PT-12
Is HLA-B8 a key MHC class I restriction element for protective T-cell epitopes in melanom
Joachim Fensterle, Uwe Trefzer, Thomas Berger, Mads Hald Andersen, Selma Ugurel, and Jürgen C. Becker (Würzburg, Germany)

Soft Tissue Sarcoma
PST-1 Role of High-Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Rescue in the Treatment of High-Dose Chemotherapy 
Bernd Kasper, Ludger Bernd, Hartmut Goldschmidt, Anthony D. Ho, Gerlinde Egerer (Heidelberg, Germany)
PST-2 Investigation of MRP1 gene amplification in Iranian AML patients using FISH technique 
Noroozi M, Ghahraman M, Golalipour M, Mahjoubi F (Tehran, Iran)
PST-3 Inhibition of survivin expression as therapeutic target in sarcoma cell lines with different p53 gene status 
Matthias Kappler, Helge Taubert, Kathi Friedrich, Frank Bartel, Karen Blümke, Hannelore Schmidt, Jürgen Dunst, Matthias Bache (Halle, Germany)
PST-4 The effect of different oxygen concentrations on the expression of carbonic anhydrase IX (CA IX) in human tumour cell lines 
Harun Said, Astrid Katzer, .Michael Flentje, Dirk Vordermark (Würzburg, Germany)
PST-5 When expression level of survivin-DEx3 is elevated - a poor outcome for soft-tissue sarcomas patients is predicted 
H. Taubert, M. Kappler, M. Bache, F. Bartel, T. Köhler, C. Lautenschläger, K. Blümke, P. Würl, H. Schmidt, A. Meye, S. Hauptmann (Halle, Germany)

Geriatric Oncology
PGO-1 Analysis of TRAIL-resistant and –sensitive renal carcinoma cell lines by comparative cDNA-array analysis 
Sebastian Heikaus, E. Caliskan, C. Mahotka, C.D. Gerharz, H.E. Gabbert, U.Ramp (Düsseldorf, Germany)
PGO-2 Expression of XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas 
Uwe Ramp, Y. Yan, C. Mahotka, S. Heikaus, T. Shibata, N. Wethkamp, J. Liebmann, Y. Guo, C.D. Gerharz, H.E. Gabbert (Düsseldorf, Germany)
PGO-3 Tiam1 overexpression is a new and independent prognostic factor in human prostate cancer 
Engers, R, Walter, A., Mueller, M., Collard, J.G., Gabbert, H.E (Düsseldorf, Germany)


Wednesday

Chemoprevention and New Drugs
PC-1 Chemoprevention of D-Galactosamine Iinduced Hepatotoxicity in Mice by Flavonoids of Garcinia Kola Seeds 
O.A. Adaramoye, EO FarombiI, EO Adeyemi and GO Emerole (Ibadan, Nigeria)
PC-2 siRNA-based approaches to pancreatic cancer 
M. Ocker, D. Neureiter, S. Zopf, M. Ganslmayer, E.G. Hahn, C. Herold (Erlangen, Germany)
PC-3 Targetting MAP kinase signalling in cancer 
Michael Agrez, Mahdu Garg, Stephen Ackland, Jun Niu and Douglas Dorahy (Newcastle, Australia)
PC-4 Cytotoxic activity in vitro of dextran-methotrexate conjugates 
Renata Budzynska, Dmitry Nevozhay, Mohamed Salah Omar, Monika Jagiello, Adam Opolski, Janusz Boratynski (Wroclaw, Poland)
PC-5 Antitumor activity and toxicity of several dextran-methotrexate conjugates with different levels of substitution 
Dmitry Nevozhay, Renata Budzynska, Mohamed Salah Omar, Monika Jagiello, Janusz Boratynski, Adam Opolski (Wroclaw, Poland)
PC-6 Targeting of tumor-relevant genes in vivo 
Frank Czubayko, Beata Urban-Klein, Stephanie Werth, Marius Grzelinski, Shaker Abuharbeid, Tobias Martens, Katrin Lamszus, Achim Aigner (Marburg, Germany)
PC-7 Combination treatment of Cilengitide® and an anti-BSP IgY antibody results in more than additive effects in MDA-MB-231GFPcells 
Jenny Mohr, Martin R. Berger (Heidelberg, Germany)
PC-8 Apple flavonoids modulate expression of genes encoding xenobiotic metabolizing enzymes in LT97 human colon adenoma cells 
Veeriah Selvaraju, Nina Habermann, Helmut Dietrich, Frank Will, Beatrice Louise Pool-Zobel (Jena, Germany)
PC-9 Overexpression and regulation of Endothelin-A-receptor in breast cancer – a promising target for antitumoral therapy 
Pia Wülfing, Martin Götte, Thorsten Persigehl, Volker Meyer, Christian Kersting, Hartmut Schmidt, Christoph Bremer, Ludwig Kiesel (Münster, Germany)
PC-10 Microsomal activation of marine compounds leading to modulation of the carcinogen-DNA adduct formation: Role of cytochrome P450s 
Jamal Arif, Mohammad Kunhi,  Yunus M. Siddiqui, Khalid El Sayed, Khaled Y. Orabi, Mohammed N. Al-Ahdal, Fahad M. Al-Khodairy (Riyadh, Saudi Arabia)
PC-11 Over-expression of MDR1 results in up-regulation of genes coding for additional detoxifying proteins 
Patrick Maier, A. Schwegler, L. Li, K. Fleckenstein, S. Laufs, S. Frühauf, W.J. Zeller, F. Wenz, C. Herskind (Heidelberg, Germany)
PC-12 Modification of cellular radioresponses induced by radiolabeled folate and folate-tetraethylenepentamine (TEPA) using 2-deoxy-D-glucose in vitro 
Vibha Shrivastava, Puja Panwar, A K Mishra, B. S. Dwarakanath (Delhi, India)
PC-13 Effect of newly synthetised oleanolic acid derivatives on viability of tumor cells 
A. Paszel, L. Zaprutko, B. Bednarczyk-Cwynar, J. Hofmann, M. Rybczynska (Poznan, Poland)
PC-14 Anti-estrogenic effects of Xanthohumol, a prenylated chalcone in hops (Humulus Lupulus L.) in vivo 
R. Hussong, J. Knauft, R. Niewöhner, N. Frank, H. Bartsch, C. Gerhäuser (Heidelberg, Germany)
PC-15 The PI3K-Akt pathway as a target for sensitising glioblastoma cells to ionising radiation 
C. Herskind, P. Maier, A. Schwegler, M. Weng, D. Milanovic, T. Körschgen, F. Wenz, F. Lohr (Heidelberg, Germany)
PC-16 Polyphenols and expression of genes for biotransformation in peripheral lymphocytes - development of a genomics-based biomarker (BIOMICS) for exposure and susceptibility 
T. Hofmann, P.Winterhalter, C.Janzowski, B. L. Pool-Zobel (Jena, Germany)
PC-17 Approaches towards improved indirubin-based anti cancer agents 
Karl-Heinz Merz, Frankie Hippe, Stephan Muehlbeyer, Stefan Schwahn, Sandra Vatter, Gerhard Eisenbrand (Kaiserslautern, Germany)
PC-18 Growth suppression of mouse mammary carcinoma by N-sulfonylpirimidine derivatives and hyperthermia 
Marko Radacic, Marina Pavlak, Jure Jercic, Biserka Zinic, Ranko Stojkovic, Matea Radacic Aumiler, Ksenija Vlahovic (Zagreb, Croatia)
PC-19 Plant material used in African traditional medicine shows antineoplastic activity in vitro and in vivo 
Cristina Voss, Ergül Eyol, Martin R. Berger (Heidelberg, Germany)
PC-20 withdrawn
PC-21 A Phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress 
Giovanni Mantovani, Madeddu C., Gramignano G., Lusso M.R., Massa E., Serpe R., Deiana L., Dessì M, Stara A, Macciò A, Astara G. (Monserrato , Italy)
PC-22 Deuterium Depletion in Cancer Treatment 
Gabor Somlyai, G. Jancso, Gy. Jakli, T. Berkenyi, M. Szabo, Z. Gyongyi, Miklos Molnar (Budapest, Hungary)
PC-23 Antisense-mediated telomerase inhibition sensitizes human bladder cancer 
Axel Meye, Kai Kraemer, Susanne Fuessel, Uta Schmidt, Manfred P. Wirth (Dresden, Germany)
PC-24 Efomycine M, an inhibitor of selectin-mediated melanoma cell adhesion - a new agent in antitumoral therapy? 
Claudia Drewniok, Michael P. Schön (Würzburg, Germany)
PC-25 Resveratrol-mediated apoptosis induction in melanoma cells does not require hydroxylation to piceatannol and is, in part, independent of caspase-activation and Bcl-2 expression 
B. Gregor Wienrich, Margarete Schön, W. Völkel, Eva.-B. Bröcker, Michael P. Schön (Würzburg, Germany)
PC-26 Peptide Aptamers – An alternative strategy for intracellular cancer targets 
Kunz C., Heinz C., Groner B (Frankfurt a.M., Germany)
PC-27 Interference with signaling components involved in breast cancer using targeted protein degradation vehicles
Corina Heinz, Claudia Bürger, Christian Kunz, Bern Groner (Frankfurt a.M., Germany)
PC-28 Mitochondrial dependent Apoptosis induced by specific Cyclooxygenase (COX)-2 Inhibitor SC-58635 in Hepatocellular Carcinoma cell lines 
Anke Haugg, A. Koch , K. Breuhahn, P. Schirmacher, M. Müller, M.A. Kern (Heidelberg, Germany)
PC-29 Effects of Linseed Lignans on Endogenous Estrogen and Phytoestrogen Metabolism 
Knust, Ulrike, Spiegelhalder, Bertold, Strowitzki, Thomas,  Owen, Robert W (Heidelberg, Germany)
PC-30 TRAIL-induced apoptosis is independent of the NO synthase pathway 
Viviana Roman, Christian Billard, Catherine Kern, Dan Hotnog, and Jean-Pierre Kolb (Bucharest, Romania)
PC-31 Trypanosoma cruzi infection and the anti-inflammatory Nimesulide increase Metallothioneins during the rat colon carcinogenesis. Links between the field cancerization theory and the role of Metallothioneins 
Sérgio Britto Garcia, Rodrigo Dornfeld Escalante, Fernando Queiroz Cunha, Waynice Neiva de Paula Garcia, Francisco Aprilli (Ribeirão Preto, Brazil)
PC-32 Inhibition of endothelial cell functions by 3-nitroflavone derivatives 
M. Lichtenberg, Dauzonne D., Bensasson, R., Gerhäuser, C. (Heidelberg, Germany)
PC-33 Isolation and purification of a novel anticancer 60 K daltons protein from the Persian Gulf sea hare, Aplysia dactylomela 
Keivan Zandi, Mohammad-Hojat Farsangi, Iraj Nabipour, Masoud Soleimani, Khosro Khajeh, Reza Sajadi, Syed-Mojtaba Jahfari, Abbas Ghad (Bushehr, Iran)
PC-34 VEGF receptor-2 expression as a target of Microtubule-destabilizing drugs 
Markus Meissner, Monika Stein, Natalia Kaprolat, Roland Kaufmann, Jens Gille (Frankfurt a.M., Germany)
PC-35 All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo 
Birgit Zirn, B. Samans, C. Spangenberg, N. Graf, M. Eilers, M. Gessler (Würzburg, Germany)
PC-36 The chemical properties and cytotoxicity in vitro of raltitrexed-carrier conjugates 
Monika Jagiello, Renata Budzynska, Dmitry Nevozhay, Mohamed Salah Omar, Adam Opolski, Janusz Boratynski (Wroclaw, Poland)

Animal Models
PA-1 Melanocortin receptors and melanoma formation in the fish Xiphophorus 
Yvonne Selz, Alexander Froschauer, Cornelia Körting, Qingchun Zhou, Christina Schultheis, Manfred Schartl and Jean-Nicolas Volff (Würzburg, Germany)
PA-2 CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer 
Dieter Saur, Barbara Seidler, Günter Schneider, Hana Algül, Roland M. Schmid (München, Germany)
PA-3 Colon cancer and exercise: morphological and molecular reactions in the colon mucosa following physical exercise 
Buehlmeyer Katja, Daniel H, Doering F, Nishino T, Schoenfelder M, Schulz T, Michna H (Munich, Germany)
PA-4 Early alteration of cytokine expression after liver irradiation in vivo 
Hans Christiansen, Bernhard Saile, Josef Dudas, Felix Reuter, Margret Rave-Fränk, Robert Michael Hermann, Clemens Friedrich Hess, Heinz Schmidberger, Giuliano Ramadori (Göttingen, Germany)
PA-5 Two experimental researches concerning our Computerized Contact Thermography application and their extrapolation in clinical oncology 
Ioan Mogos, Florin Badulescu, Mihai Mogos, Roxana R.Garleanu, Violeta Garleanu (Bucharest, Romania)
PA-6 B-Raf and Ha-ras Mutations in chemically induced mouse liver tumors 
Maike Jaworski, Albrecht Buchmann, Peter Bauer, Olaf Riess, Michael Schwarz (Tübingen, Germany) 
PA-7 Mechanisms of carcinogenesis in reflux disease 
Martin Fein, H. Stopper, M. Herderich (Würzburg, Germany)
PA-8 The anti-obesity agent Orlistat increases preneoplastic markers in the colonic mucosa of rats treated with a chemical carcinogen 
Waynice Neiva de Paula Garcia, Luane Taísa da Costa Barros, Flávia Martinello, Patrícia Modiano, Sérgio Akira Uyemura, Sérgio Britto Garcia (Ribeirão Preto, Brazil)
PA-9 A Kidney-Specific Knockout Model of the VHL Tumor Suppressor Gene in the Mouse 
Koesters, R and M von Knebel Doeberitz (Heidelberg, Germany)
PA-10
Animal models for DNA vaccination against prostate cancer using PSA encoding plasmids
Joachim Fensterle, Vera Schwartz, Hubertus Riedmiller and Ulf R. Rapp (Würzburg, Germany)

Homeostatic Growth Control
PH-1 An In-Vivo and In-vitro investigation to assess the role of High Homocysteine in DNA damage 
Mehboob Ali, Sageer A Khan, S. Raisuddin (New Delhi, India)
PH-2 VEGF expression in AsPC-1 pancreatic cancer cells is dependent on IRS-2, FAK and cell-cell contact 
Neid M, Tannapfel A, Datta K, Mukhopadhyay D and Wittekind Ch (Leipzig, Germany)
PH-3 BAG-1: possible effector in the cell survival control by C-Raf and Bcl-2 
Manickam Janakiraman, Stefan Wiese, Rudolf Götz, Michael Sendtner, U.R.Rapp, Jakob Troppmair (Innsbruck, Austria)
PH-4 E2F-1 activates the polycomb group gene BMI1 
Werner Lutz, Katrin Nowak, Daniel Fehr, Kornelius Kerl, Christoph Kramps (Marburg, Germany)
PH-5 Expression Profiles of Differentially Expressed Genes of Rat Mammary Adenocarcinoma in Various Tumor Cell Lines and Effects of Some Antioxidants Secil Certel, Hatice Gunes, Mert Sudagidan,  (Izmir, Turkey)
PH-6 Study of MDR1 gene association with multidrug resistance phenotype in Iranian AML patients 
Ghahraman M, Noroozi M, Golalipour M, Mahjoubi F (Tehran, Iran)
PH-7 The role of RASSF1A polymorphisms in apoptosis and cancer development 
Claudia Seidel, Undraga Schagdarsurengin, Reinhard Dammann (Halle, Germany)
PH-8 Oncogene-induced proliferation of human colon carcinoma cells is linked to CCAAT-/Y-box-binding motifs in deregulated signalling target genes 
Reinhold Schäfer, Karsten Jürchott, Ralf-Jürgen Kuban, Till Krech, Heiko Valtin, Nils Blüthgen, Ulrike Stein, Wolfgang Walther, Hans-Peter Herzel (Berlin, Germany)
PH-9 The function of S100 proteins in the process of squamous skin carcinogenesis 
Michiel van der Sanden, Lars Hummerich, Regina Mueller, Ingeborg Vogt, Meinhard Hahn, Gerhard Fürstenberger, Cornelia Mauch, Peter Lichter, Jochen Hess and Peter Angel (Heidelberg, Germany)
PH-10 Inhibition of casein kinase I delta alters mitotic spindle formation and induces apoptosis in trophoblast cells 
Knippschild U., Bamberger A-M, Aslan B, Kurth M, Speidel, D, Löning T, Frank H-G, Kaufmann P, Löhler J, Henne-Bruns D, Stöter M (Ulm, Germany)
PH-11 Molecular characterization of genes involved in tumor progression: NDRG1 is necessary for p53-dependent apoptosis 
S. Stein, E. K. Thomas, B. Herzog, M. D. Westfall, J. V. Rocheleau, N. Habtemichael, S. Deckert, P. Liang and R. H. Stauber (Frankfurt a.M., Germany)
PH-12 Synergistic induction of apoptosis in acute lymphatic leukemia by VPA and dexamethasone 
Alexandra Groß, Ingrid Bartsch, Marc Buchwald and Thorsten Heinzel (Frankfurt a.M., Germany)
PH-13 Functional antagonism between Myc and p27 in differentiation and proliferation of K562 cells 
Juan Carlos Acosta, M. Dolores Delgado, Javier León, John Sedivy (Santander, Spain)
PH-14 Neovascular Targeting by EndoTAG-2 (MBT-0312) Inhibits Growth of Subcutaneous Mouse Tumors 
Boris Brill, Alexander Werner, Christoph Brunner; Uwe Michaelis,  Michael Teifel, Bernd Groner (Frankfurt a.M., Germany)
PH-15 Inhibition of early steps of metastasis by inhibition of Focal adhesion kinase (FAK) 
Katja M. Fisch, Anke von Sengbusch, Peter Gassmann, Jörg Haier (Münster, Germany)
PH-16 Characterisation of EGFR family proteins and their ligands in Xiphophorus 
Juliette Laisney, Ana Gómez, Claudia Wellbrock, Manfred Schartl1, Svenja Meierjohann (Würzburg, Germany)
PH-17 Search for an alternative tumor suppressor gene on chromosome 17p telomeric to p53 
Heike Stöcklein, Tiemo Katzenberger, Sylvia Höller, German Ott, Hans Konrad Müller-Hermelink und Jörg Kalla (Würzburg, Germany)
PH-18 Withdrawn
PH-19 Isolation of siRNAs inhibiting Myc induced apoptosis by retroviral shRNA-library screening 
Michael Wanzel, Steffi Herold and Martin Eilers (Marburg, Germany)
PH-20 p53 Family Members in Muscle Differentiation and Rhabdomyosarcoma Development 
Hakan Cam, Lars Hofmann, Michaela Beitzinger, Claudia Oswald, Nadja Karl, Nicole Kirchhof, Peter Friedl, Thorsten Stiewe (Würzburg, Germany)
PH-21 Regulation of Telomerase Activity by p73 
Michaela Beitzinger, Rasa Beinoraviciute-Kellner, Lars Hofmann,Nadja Karl, Thorsten Stiewe (Würzburg, Germany)
PH-22 Function of TGF-beta receptor type IIB 
Daniel Horbelt, Manuel Bauer, Petra Knaus (Berlin, Germany)
PH-23 The oncogenic receptor Xmrk and its interactors – insights into mechanisms of melanomagenesis 
Janka Teutschbein, Christiane Stuhlfelder, Manfred Schartl, Svenja Meierjohann (Würzburg, Germany)
PH-24 BLIMP-1 induces plasma cell differentiation in diffuse large B-cell lymphoma 
Mindaugas Andrulis, Friederike Berberich-Siebelt, Hans-Martin Jäck, Petr Starostik, Martina Hartmann, German Ott, Hans Konrad Müller-Hermelink and Axel Greiner (Würzburg, Germany)
PH-25 WS5, the avian homolog of the human melanoma antigen encoding Pmel17 gene, is a direct target of oncogenic transcription factor Myc 
Fritz Reiter, Markus Hartl, Petra Desch, Klaus Bister (Innsbruck, Austria)
PH-26 Analysis of activated vs. wild type H-Ras localization in different plasma-membrane microdomains 
Agudo-Ibañez, L., Crespo, P. (Santander, Spain)
PH-27 Identification of proteins controlling proliferation and differentiation of mammary epithelial cells
Sylvane Desrivières, Thorsten Prinz, Nahomi Castro-Palomino Laria, Lore Florin, Karsten Kuhn, Jürgen Schäfer, Christian Hamon, Peter Angel and Bernd Groner (Frankfurt a.M., Germany)

Tumor Cell Metabolism
PTC-1 Early Detection of Malignancy in Primary Sclerosing Cholangitis Using Quantitative DNA Analysis: Prognostic Relevance for Selecting Patients for Liver Transplantation 
Guido Schumacher, H. Al-Abadi, H. Abou-Rebyeh, S. Jonas, R. Neuhaus, Th. Berg, P. Neuhaus (Berlin, Germany)
PTC-2 Cellular response mechanisms associated to tumour progression and metastasis after oxidative stress treatment and the influence of adjuvant alpha-tocopherol administration 
Christine Lambert, Oliver Thews, Hans K. Biesalski, Jürgen Frank (Stuttgart, Germany)
PTC-3 Induction of apoptosis in human hepatocellular carcinoma HepG2 cells by reoxygenation after chronic hypoxia 
Franz Y. F. Ho, W.P. Tsang, T. T. Kwok (Hong Kong, China)
PTC-4 TNF alpha effects on PC cell 
Jurisic V, Bogdanovic G, Srdic T, Kojic V, Kraguljac (Kragujevac, Serbia)
PTC-5 Relevance of Glucose Metabolism for the Radiation Sensitivity of Xenotransplanted Human Tumors 
Verena Banning, Stefan Walenta, Daniel Zips, Ala Yaromina, Michael Baumann, Wolfgang Mueller-Klieser (Mainz, Germany)
PTC-6 A Novel Bioluminescence Imaging Method for the Quantification of Local Pyruvate Concentrations in Freeze-Clamped Tissue 
Ulrike Sattler, Stefan Walenta, Wolfgang Mueller-Klieser (Mainz, Germany)
PTC-7 The role of A-Raf in migration, proliferation and metabolism explored by overexpression and RNAi experiments in glioblastoma cell-lines and primary cells 
Carsten Hagemann, Christoph Meyer, Birgit Werner, Stefanie Gerngras, Sieglinde Kühnel, Jelena Stojic, Giles Hamilton Vince, Ulf Rüdiger Rapp, Klaus Roosen (Würzburg, Germany)
PTC-8 Novel pro-apoptotic genes in CD95- mediated apoptosis identified by technical knock out (TKO) screening 
C Mahotka, M Hassan, CD Gerharz, HE Gabbert (Düsseldorf, Germany)
PTC-9 CD95-mediated apoptosis in renal cell carcinoma (RCC) cell lines is uneffected by overexpression of the apoptosis enhancer Daxx 
Wethkamp N, Hassan M,Suschek CV, Gabbert HE, Gerharz CD, Mahotka (Düsseldorf, Germany)
PTC-10 AP-1 activation in avian fibroblasts transformed by the v-myc/v-mil(raf) oncogenes leads to specific induction of osteopontin which is implicated in cell transformation 
Markus Hartl, Antonios Karagiannidis, Klaus Bister (Innsbruck, Austria)
PTC-11 HRS3 triggers apoptosis in ovarian carcinoma cells through inhibition of PP2A 
Nazarenko Irina, Kerstin Lehmann, Reinhold Schaefer and Christine Sers (Berlin, Germany)
PTC-12 5-Fluoruracil treatment alters Ferredoxin-reductase-mRNA splice variant ratios in colorectal cancer patients: Impact on therapeutical response 
Mark Schneider, M. Tanaka, S. Kato, B. Blömeke (Aachen, Germany)
PTC-13 Sonic hedgehog is a potent inducer of osteomimicry in prostate carcinoma cells 
Tanja Neidhart,  Karin Ackermann, Walter Pyerin (Heidelberg, Germany)
PTC-14 Inducible Expression of Human 15-Lipoxygenase-2 and the Homologous Mouse 8-Lipoxygenase in Premalignat Mouse Keratinocytes: Association with Growth Inhibition 
Dorothea Schweiger, Gerhard Fürstenberger and Peter Krieg (Heidelberg, Germany)
PTC-15 Electronic and biochemical imaging of metabolic parameters in tumor cells 
Otto, A.M., Motrescu, E. R., Brischwein, M., Wolf, B. (Munich, Germany)
PTC-16 Ligand-induced EGFR Degradation after Stimulation with High Concentrations of EGF is Implicated in Up-Regulation of p21WAF1/CIP1 in HNSCC Cell Lines 
Robert Mandic, Wolfgang Meissner, Jessica Rüddel, Michael Bette, Eberhard Weihe, Rolf Müller, Jochen Alfred Werner (Marburg, Germany)
PTC-17 The PI3-kinase-Akt-/mTor Signaling Pathway Controls Imatinib Resistance Development 
Andreas Burchert, Ying Wang, Nicolas von Bubnoff, Sabine M. Brüsselbach, Peter Paschka, Dali Cai, Justus Duyster, Andreas Hochhaus and Andreas Neubauer (Marburg, Germany) 
PTC-18 Establishment of a lentiviral-mediated system to determine the physiological role of proteins in the developing mammary gland
Vida Vafaizadeh, Boris Brill, Bernd Groner and Sylvane Desrivières (Frankfurt, Germany)

Gastro Intestinal Tumors
PGI-1 Laboratory-Immunology Indicators as Prognostic Factors of Patients with Colon and Rectum Cancer 
S. Maksimovic, S. Lovric (Bijeljina, Bosnia and Hercegovina)
PGI-2 IKKalpha regulates G1 phase progression of pancreatic cancer cells by stabilization of the cyclin-dependent kinase inhibitor p27Kip1 
Schneider, Günter, Dieter, Saur, Jens, Siveke, Roland M. Schmid (Munich, Germany)
PGI-3 Solid Tumors of the Pancreas Expressing c-kit (CD117) and CD34 
U. Pauser, Maria Teresa Simões da Silva, M.D. 2, Jörg Placke, M.D. 3, David S. Klimstra, M.D.4, Günter Klöppel (Kiel, Germany)
PGI-4 Direct Interaction of EpCAM and the Tight Junction Protein Claudin-7 on Metastasizing Tumor Lines: A Role in Tumor Progression? 
Markus Ladwein, Ulrich-Frank Pape, Martina Schnölzer, Herbert Spring, Werner W. Franke und Margot Zöller (Heidelberg, Germany)
PGI-5 Feasibility and limits of an orthotopic human colon cancer nude mouse model 
Thalheimer Andreas, Büter M, Gattenlöhner S, Timmermann W, Waaga-Gasser AM, Thiede A, Meyer D (Würzburg, Germany)
PGI-6 Modulation of gene expression in isolated primary human colonocytes, a novel approach in nutrigenomics 
Julia Sauer, Richter, K.K., Pool-Zobel, B.L (Jena, Germany)
PGI-7 Growth suppressive effect of gastrin on CCK2-receptor expressing human colon cancer cells by induction of apoptosis in vitro and in vivo 
Susanne Müerköster, Anett Isberner, Alexander Arlt, Maike Witt, Ewelina Blaszczuk, Babette Reimann, Veronika Werbing, Ulrich R. Fölsch, Frank Schmitz, Heiner Schäfer (Kiel, Germany)
PGI-8 Permeability Glycoprotein and tumor grad in Squamous cell carcinoma of the head and neck 
Mohammed Abd Elmotaal Gomaa, Mahmoud Saleh, Raof Isac, and  Wafaa Aref (Minia, Egypt)
PGI-9 P53 and Bcl2 in cancer Larynx 
Mohammed A. Gomaa, Heba Tawfik, Abd elaziz elsherif, and Mostafa Hamad (Minia, Egypt)
PGI-10 Contact Computerised Thermography in Surveillance of Symptomatic Patients with High Risk for Colorectal Cancer 
Ioan Mogos, Miihai Mogos, Lucian Raducan, Roxana Garleanu (Bucharest, Romania)
PGI-11 Hypermethylation of HPP1 and hMLH1 in esophageal adenocarcinoma and its precursor lesions 
H. Geddert, E. Iskender, A. Florl, C. Franke, H. E. Gabbert, M. Sarbia (Düsseldorf, Germany)
PGI-12 The HER2 heterodimerization inhibitor Pertuzumab is active against colon cancer cells in vitro and in vivo 
Niko Andre, Anna Schoeneck, Susanne Klein-Scory, Max Hasmann, Irmgard Schwarte-Waldhoff, Wolff Schmiegel and Anke Reinacher-Schick (Bochum, Germany) 
PGI-13 Establishment of an orthotopic pancreatic cancer nude mice model for a better examination of Minimal residual disease 
Dominik Stehle, Christoph Otto, Christine Lesch, Arnulf Thiede, Bertram Illert (Würzburg, Germany)
PGI-14 Immune escape of hepatic and gastrointestinal cancer: Secretion of soluble complement inhibitors 
Ziegler Stefanie, Buech Thomas, Soliani Paolo, Zerbini Alessandro, Missale Gabriele, Del Rio Paolo, Sianesi Mario, Kirschfink Michael (Parma, Italy)
PGI-15 Aberrant promoter methylation profile in low and high grade gastric lymphomas 
Jae-Hyuk Lee, Jae-kyun Ju, Dong-Yi Kim, Shin-Kon Kim, and Sang-Woo Juhng (Kwangju, Republic of Korea)
PGI-16 Mechanistic and therapeutic impact of Insulin-like Growth Factor (IGF)-II in human hepatocarcinogenesis 
Tanja Nussbaum, Sebastian Vreden, Kai Breuhahn, Peter Schirmacher (Heidelberg, Germany)
PGI-17 Differential subcellular distribution and function of Siah-1 in human hepatocarcinogenesis 
Kai Breuhahn (Heidelberg, Germany)
PGI-18 Regulation of the anti-Tumor-Immune Response in Patients with Colorectal Carcinoma 
Bueter M, Gasser M, Gerstlauer C; Grimm M; Nichiporuk E; Talheimer A, Thiede A,; Meyer D,  Waaga-Gasser (Würzburg, Germany)
PGI-19 Assessment of relevant prognostic tumor markers involved in apoptosis in patients with colorectal cancer 
Martin Gasser, Grimm M; Bueter M,  Hom S, Nichiporuk E, Gerstlauer C; Thalheimer A,  Koenigshausen M; Thiede A,  Meyer D, Waaga-Gasser (Würzburg, Germany)
PGI-20 On the way to a prognostic chip for colorectal carcinomas 
C. Astrosini, W. Kemmner, P.M. Schlag (Berlin, Germany)
PGI-21 FUFOXIRI: A protocol with weekly administration of 5-Fluorouracil (5-FU), Folinic Acid (FA), Oxaliplatin (OHP), and Irinotecan (CPT-11) for patients with metastatic gastric or colorectal cancer 
Stefan Peinert, W. Grothe, T. Kegel, K. Jordan, D. Arnold, H.-J. Schmoll, A. Grothey, R. Behrens (Halle, Germany)
PGI-22 The variability of MLH1 promoter methylation in tumors of HNPCC suspected patients 
Alemayehu Aster, Haider Ritva, Fridrichova Ivana (Bratislava, Slovakia)
PGI-23 Activity of Cetuximab plus Oxaliplatin and Capecitabine (CAPOX) in patients with metastatic colorectal cancer (MCRC) refractory to Oxaliplatin and Irinotecan 
W. Grothe, D. Arnold, S. Peinert, R. Siewczynski, K. Jordan, W. Voigt, J. Boehme, L. Mantovani-Loeffler, H. Schmoll (Halle, Germany)
PGI-24 A severe case of liver failure probably related to gemcitabine 
R. Kath, H.P. Dienes, G. Gerken, P. Hildegard, (Ole) Peters (Essen, Germany)
PGI-25 Study on the rate of recommended standards at the diagnostic radiology units of the hospitals affricated to the Mazandaran University of medical sciences 
Ali Rahimi (Sari, Iran)

Neuroendocrine and Endocrine Tumours
PN-1 Papillary Thyroid Carcinoma (PTC) – Recurrences and Prognosis 
Sinisa Maksimovic, S. Lovric, M. Popovic (Bijeljina, Bosnia and Hercegovina)
PN-2 Biological significance of Aminopeptidase N and Dipeptidyl peptidase IV in thyroid carcinomas 
Astrid Kehlen, Jürgen Langner, Coung Hoang-Vu (Halle, Germany)
PN-3 B-Raf specific antibody responses in patients with papillary thyroid carcinoma
Joachim Fensterle, Johannes Biko, Veronika Heimbach, Ulf R. Rapp and Christoph Reiners (Würzburg, Germany)


All Copyrights by
13th AEK/AIO CANCER CONGRESS WÜRZBURG 2005
Disclaimer